• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Syniverse Holdings

Syniverse Holdings

  1. All
  2. 3rd Party
  3. Investing
  1. Enanta Announces that AbbVie’s MAVIRET™ (glecaprevir/pibrentasvir) Received Approval in Japan for the Treatment of All Major Genotypes (GT1-6) of Chronic Hepatitis C

    Enanta Announces that AbbVie’s MAVIRET™ (glecaprevir/pibrentasvir) Received Approval in Japan for the Treatment of All Major Genotypes (GT1-6) of Chronic Hepatitis C

  2. March's Stock Red Flags

    Three stocks we think investors should be wary of.

1

©2017 Morningstar Advisor. All right reserved.